

Conference Committee

Truus Janse-de Hoog

Staff member MEB, European cluster, Chair CMD(h),
Medicines Evaluation Board, The Netherlands

Isabelle Moulon

Head of Medical Information Sector, Chair of Quality Review of
Documents (QRD), EMEA, EU

Alexios Skarlatos

Quality Review of Documents (QRD), EMEA, EU

Overview

In this joint workshop EMEA and Member States representatives will discuss their experiences in the assessment of user tests and give recommendations how the test can contribute to improve the quality of a package leaflet. Industry and Member States representatives will present their experiences on bridging studies and justifications for exemption from user consultation.

What are the lessons learned so far? Representatives from European Commission, Patient Organisations and Academia will give their views on possibilities to improve the quality of the package leaflet.

Who will attend?

- Regulators / Assessors from National -/ Competent Authorities involved in the evaluation of User Testing (UT) reports
- Representatives of pharmaceutical industry creating package leaflets
- Representatives of pharmaceutical industry responsible for user consultation
- Representatives of CROs directly involved in conducting User Testing
- EMEA representatives

Objectives

To provide updates and experiences with the assessment of user consultation tests of package leaflets three years after the implementation of the New Medicines Legislation. Discuss with all stakeholders (Regulators, Industry, Clinical Research Organisations (CROs), Academia and Patient Representatives) how to achieve good quality package leaflets.

Hotel Information

DIA Europe has booked a number of rooms at the:

Devonport House

King William Walk, Greenwich,
London, SE10 9JW
United Kingdom

<http://www.deverevenues.co.uk/find-venue/devonport-house.html>

Booking details

Rooms: Single rooms

Rates: £119.00 per night

Details: Rate includes breakfast and 17.5% VAT

To reserve a room please contact the Devonport House

Tel.: +44 208 269 5400

Fax: +44 208 269 5401

Email: devonport@deverevenues.co.uk

To receive this special rate please mention the DIA Reservation code:
500 723 10

Important

To ensure accommodation at the Devonport House please complete your reservation by **October 17, 2008**

For further information, please visit: www.diahome.org > Select **Educational Offerings** > Keyword: **08112**. To secure your place at the workshop, please complete and fax back the enclosed registration form or register online. The DIA Europe Customer Services Team will be pleased to answer your questions and assist you with the registration process. Call us on +41 61 225 51 51 from Monday to Friday, 08:00-17:00 CET, or email: diaeurope@diaeurope.org



The Drug Information Association (DIA) has been approved as an "Authorized Provider" by the International Association for Continuing Education and Training (IACET), 8405 Greensboro Drive, Suite 800, McLean, VA 22102. DIA is authorised by IACET to offer 0.6 CEUs for this programme. If you would like to receive a statement of credit, you must attend the programme, return your evaluation form and complete the online credit request process through My Transcript at www.diahome.org. Participants will be able to download a statement of credit upon successful submission of the credit request.

Disclosure Policy: It is Drug Information Association policy that all faculty participating in continuing education activities must disclose to the programme audience (1) any real or apparent conflict(s) of interest related to the content of their presentation and (2) discussions of unlabelled or unapproved uses of drugs or medical devices. Faculty disclosures will be included in the course materials.



Joint DIA – EMEA – CMD(h) Workshop on

USER TESTING

December 5, 2008

Devonport House, London, UK

PROGRAMME

ID# 08112

Programme

08.00-09.00

Registration and Welcome Coffee

09.00-10.30

Session 1

USER CONSULTATION – THREE YEARS OF EXPERIENCE IN CONDUCTING AND REVIEWING USER TESTS

Session Chairperson:

Alexios Skarlatos, Quality Review of Documents (QRD), EMEA, EU

EMEA has carried out an analysis of the User Testing reports submitted by applicants / Marketing Authorisation Holders (MAHs) for the period 2005-2008 and the way these were handled by the member states assessors. During this session key stakeholders will share their experiences of the first three years following the implementation of the User Testing requirement.

EMEA Experience

Alexios Skarlatos, Quality Review of Documents (QRD), EMEA, EU

- Summary of findings / recommendations drawn from all User Testing reports submitted to the EMEA for the period 2005-2008
- Handling of assessment by Rapporteur / Co-Rapporteur

Pharmaceutical Industry Experience

Petra Baddack, GRA - Head of Europe, Regulatory Affairs Coordination, Solvay Pharmaceuticals GmbH, Germany

Member State Experience

MHRA representative invited

Clinical Research Organisation Experience

Theo Raynor, Chairman, Luto Research Ltd., UK

10.30-11.00

Coffee break

11.00-12.30

Session 2

BRIDGING STUDIES – JUSTIFICATIONS FOR EXEMPTION FROM USER TESTING REQUIREMENT – DESIGN AND LAYOUT

Session Chairperson:

Truus Janse-de Hoog, Staff member MEB, European cluster, Chair CMD(h), Medicines Evaluation Board, The Netherlands

CMD(h) has published a guidance paper on bridging studies. The QRD group of EMEA also has ongoing discussions for which applications exemptions from user consultation can be granted. In this session representatives from National Agencies and generic industry will present their experiences.

Bridging Data: Guidance Documents and Experience at National Level

Klaus Menges, Head of Scientific Quality Assurance, BfArM, Germany

The Case of Generic Products

Susan De Stasio, Head EU Regulatory Affairs, Arrow Generics Ltd., Chair European Generic Medicines Association (EGA) Regulatory and Scientific Affairs Committee, UK

Member States Experience

Anna Wachnik-Swiecicka, Office for Registration of Medicinal Products, Medical Devices and Biocides, Poland

12.30-13.30

Lunch

13.30-15.00

Session 3

HEALTH LITERACY - IS IT POSSIBLE TO WRITE LEAFLETS THAT ARE UNDERSTANDABLE FOR ALL PATIENTS?

Session Chairperson:

Ilaria Passarani, Health Policy Officer, BEUC, The European Consumers' Organisation and EMEA Patient & Consumer Working Party (EMEA PCWP), , Belgium

Inadequate health literacy may result in difficulty following instructions and taking the medicine properly. Can a single package leaflet answer the needs of all the patients irrespective of their background? This session will look at the extent of the problem and possible ways to address the diversity of the package leaflet audience.

Health Literacy in EU

European Commission representative invited

The Academic Perspective

Leo Lentz, Director Education Dutch Language, University of Utrecht, The Netherlands

Patient's Views

Ilaria Passarani, Health Policy Officer, BEUC, The European Consumers' Organisation and EMEA Patient & Consumer Working Party (EMEA PCWP), , Belgium

15.00-15.30

Coffee break

15.30-17.00

Session 4

LESSONS LEARNED: THE WAY FORWARD

Co-Session Chairpersons:

Truus Janse-de Hoog, Staff member MEB, European cluster, Chair CMD(h), Medicines Evaluation Board, The Netherlands

Isabelle Moulon, Head of Medical Information Sector, Chair of Quality Review of Documents (QRD), EMEA, EU

Design and Layout – Key for a Successful Package Leaflet

Helen Darracott, Director of Legal and Regulatory Affairs, PAGB, UK

Lessons Learned: The Way Forward – CRO's Perspective

Joerg Fuchs, PAINT – Consult, Germany

Lessons Learned: The Way Forward – Member State Perspective

Kim Sherwood, Regulatory Administration Department, Medical Products Agency (MPA), Sweden

Panel Discussion

17:00

End of Workshop

FAX YOUR COMPLETED REGISTRATION FORM TO: +41 61 225 51 52

The DIA Europe Customer Services Team will be pleased to assist you with your registration.

Please call us on +41 61 225 51 51 from Monday to Friday between 08:00 and 17:00 CET, or email diaeuropa@diaeurope.org

REGISTRATION FORM - ID# 08112

JOINT DIA - EMEA - CMD(h) WORKSHOP ON USER TESTING
DECEMBER 5, 2008 - DEVONPORT HOUSE, LONDON, UK

If DIA Europe cannot verify your membership upon receipt of registration form, you will be charged the non-member fee. Registration includes conference material and refreshment breaks for the value of € 150.00.

Registration will be accepted by mail, fax, email or online at www.diahome.org



	MEMBER		NON-MEMBER (with optional membership)			NON-MEMBER (without optional membership)	
	FEE	TOTAL	FEE	MEMBERSHIP	TOTAL	FEE	TOTAL
Industry	€ 780.00	€ 780.00 ☐	€ 780.00	€ 130.00	€ 910.00 ☐	€ 910.00	€ 910.00 ☐
Charitable/Non-profit/ Academia (Full-Time)	€ 585.00	€ 585.00 ☐	€ 585.00	€ 130.00	€ 715.00 ☐	€ 715.00	€ 715.00 ☐
Government (Full-Time)	€ 390.00	€ 390.00 ☐	€ 390.00	€ 130.00	€ 520.00 ☐	€ 520.00	€ 520.00 ☐
☐ TOTAL AMOUNT DUE: € _____							

NOTE: Payment of registration fees must be received before commencement of the meeting.

STUDENT RATE AVAILABLE! PLEASE CONTACT DIA EUROPE FOR MORE INFORMATION.

08112DIAWE

Please indicate your areas of professional interest:

- | | | | |
|---|--|---|---|
| ☐ AH - Academic Health Centres | ☐ FI - Finance | ☐ MN - Manufacturing: Drug Substance, Drug Product, Packaging | ☐ PK - Pharmacokinetics / Metabolism / Pharmacodynamics |
| ☐ AM - Alternative / Herbal Medicine | ☐ EC - e-Clinical | ☐ MW - Medical/Scientific Writing | ☐ PM - Project Management |
| ☐ BT - Biotechnology | ☐ GC - GCP | ☐ NC - Non-clinical Safety & Efficacy/Toxicology | ☐ PP - Public Policy / Law |
| ☐ CD - Clinical Data Management | ☐ GE - Generic Manufacturing | ☐ NH - Natural Health Products | ☐ QC - Quality Control / Quality Assurance |
| ☐ CH - Chemistry / Drug Design | ☐ GL - GLP | ☐ OS - Outsourcing / Virtual Development | ☐ RA - Regulatory Affairs / Policy / Drug or Device Approval / GRP |
| ☐ CL - Clinical Laboratory Data | ☐ GM - GMP | ☐ OT - Over the Counter | ☐ RD - Research & Development / Strategic Issues |
| ☐ CM - CMC | ☐ IM - Information Management | ☐ PC - Pharmaceuticals | ☐ ST - Statistics / Biostatistics / Mathematical Modelling |
| ☐ CP - Clinical Safety/Pharmacovigilance | ☐ IMP - Impact | ☐ PD - Professional Development | ☐ TR - Training |
| ☐ CR - Clinical Research & Development | ☐ IS - Investigator Site | ☐ PE - Pharmacoeconomics / Quality of Life / Health Economics / Outcomes Research / Managed Healthcare | ☐ VA - Validation |
| ☐ CS - Clinical Supplies | ☐ IT - Information Technology / e-Business | ☐ PH - Pharmacology | |
| ☐ DC - Dictionaries / Data Standards | ☐ MA - Marketing / Advertising | | |
| ☐ DE - Devices | ☐ MC - Medical Communications / Information | | |
| ☐ DM - Document Management | ☐ MH - Managed Healthcare | | |

REGISTRANT

☐ Prof. ☐ Dr. ☐ Ms. ☐ Mr.

TO MAKE REGISTRATION EVEN SIMPLER, PLEASE ATTACH THE REGISTRANT'S BUSINESS CARD

Last Name

First Name

Company

Job Title

Street Address / P.O. Box

Postal Code

City

Country

Telephone

Telefax (Required for confirmation)

Email (Required for confirmation)

Please indicate your professional category: ☐ Academia ☐ Government
☐ Industry ☐ Contract Service Organisation

PAYMENT METHODS

☐ Please charge my credit card - credit card payments by VISA, Mastercard or AMEX can be made by completing the relevant details below. Please note that other types of credit card cannot be accepted.

☐ VISA ☐ MC ☐ AMEX

Card Number

Exp. Date

Cardholder's Name

Date

Cardholder's Signature

☐ Cheques should be made payable to: Drug Information Association. Mail your cheque together with the registration form to facilitate identification of attendee to: DIA, Elisabethenanlage 25, Postfach, 4002 Basel, Switzerland.

☐ Bank transfers When DIA Europe completes your registration, an email will be sent to the address on the registration form with instructions on how to complete the bank transfer. Payment should be in EURO and your name and company, as well as the Meeting ID# 08112 and invoice number, must be included on the transfer document to ensure correct allocation of your payment. Payments must be net of all charges and bank charges must be borne by the payee.

Persons under 18 are not allowed to attend DIA meetings.

CANCELLATION POLICY All cancellations must be in writing and be received at the DIA office by 17:00 CET on November 27, 2008.

Cancellations received in writing on or before November 27, 2008 - Cancellations received by the date above are subject to an administrative fee: Full Meeting Cancellation: Member/Non-member = € 200.00 - Government/Academia/Non-profit (Member/Non-member) = € 100.00. Registrants who do not cancel by the date above, and do not attend, will be responsible for the full registration fee. Registrants are responsible for cancelling their own hotel reservations. DIA Europe reserves the right to alter the venue if necessary. If an event is cancelled, DIA Europe is not responsible for airfare, hotel or other costs incurred by registrants.

Transfer Policy

You may transfer your registration to a colleague prior to the workshop start but membership is not transferable. Substitute registrants will be responsible for the non-member fee, if applicable. Please notify DIA Europe office of any such substitutions as soon as possible.

Hotel and travel reservations should be made ONLY after receipt of written registration confirmation from DIA Europe.
If you have not received your confirmation within five working days, please contact DIA Europe.

DIA Europe: Elisabethenanlage 25, Postfach 4002 Basel, Switzerland / Phone: +41 61 225 51 51 / Fax: +41 61 225 51 52
Email: diaeuropa@diaeurope.org / www.diahome.org